Follow

CS MEDICA A/S: CFO Gitte Lund Henriksen buys more shares in the Company

03 June 2022 - 11:12

CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the CFO of the Company, Gitte Lund Henriksen, has today acquired 10 159 shares in CS MEDICA at a price of 5,88, amounting to a total value of 59 824,52 DKK including commission.

CFO and board member of CS MEDICA, Gitte Lund Henriksen, has purchased 10 159 shares in the open market at a price of DKK 5,88 per share, corresponding to a total purchase of 59 824,52 DKK including commission. The transaction has been disclosed in the Danish financial supervisory register. Following the transaction, Gitte Lund Henriksen owns 4 037 000 CS MEDICA shares.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: [email protected]
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.

Provided by: Cision
Spotlight Stock Market (Sweden)
CS Medica A/S
CS Medica fully owns two Denmark-based subsidiaries: Galaxa Pharma A/S and CanNordic A/S, whereby CanNordic A/S is a registered Medical Device product developer and Galaxapharma A/S is a product distributor in the Nordic Region....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More